The effects of antisense to G(iα2) on opioid agonist potency and G(iα2) protein and mRNA abundance in the mouse

Molecular Brain Research

Volumn 59, Issue 2, 1998, Pages 247-255

  Shen, Ji ^a   Shah, Sukrut ^a   Hsu, Helen ^a   Yoburn, Byron C ^a  

^a Department of Pharmacy and Administrative Sciences   (United States)

Author keywords

Analgesia; Antisense oligodeoxynucleotide; cAMP; G protein; Immunoblotting; Morphine; Mouse; mRNA; Opioid potency; RT PCR; Striatum

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CYCLIC AMP; GUANINE NUCLEOTIDE BINDING PROTEIN; MESSENGER RNA; ANTISENSE OLIGONUCLEOTIDE; ENKEPHALIN[2 ALANINE 5 LEUCINE]; FORSKOLIN; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; MORPHINE; NARCOTIC ANALGESIC AGENT; OPIATE PEPTIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; IMMUNOBLOTTING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CHEMISTRY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION; GENETICS; METABOLISM; NOCICEPTIVE RECEPTOR; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANALGESICS, OPIOID; ANIMALS; CORPUS STRIATUM; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ENKEPHALIN, LEUCINE-2-ALANINE; FORSKOLIN; GENE EXPRESSION; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; MALE; MICE; MORPHINE; NOCICEPTORS; OLIGONUCLEOTIDES, ANTISENSE; OPIOID PEPTIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0032585014     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(98)00133-8     Document Type: Article

References (48)

1. Adams J.U., Paronis C.A., Holtzman S.G. Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using beta-funaltrexamine. J. Pharmacol. Exp. Ther. 255:1990;1027-1032.
2. Albert P.R., Morris S.J. Antisense knockouts: molecular scalpels for the dissection of signal transduction. Trends Pharmacol. Sci. 15:1994;250-254.
3. Bodnar R.J., Paul D., Rosenblum M., Liu L., Pasternak G.W. Blockade of morphine analgesia by both pertussis and cholera toxins in the periaqueductal gray and locus coeruleus. Brain Res. 529:1990;324-328.
4. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
5. C. Cazenave, C. Helene, Antisense oligonucleotides, in: Antisense Nucleic Acids and Proteins: Fundamental and Applications, 1991, pp. 1-6.
6. Chang S.C., Lutfy K., Sierra V., Yoburn B.C. Dissociation of opioid receptor upregulation and functional supersensitivity. Pharmacol. Biochem. Behav. 38:1991;853-859.
7. s-stimulated adenylate cyclase. J. Neurochem. 50:1988;543-553.
8. Childers S.R., Lariviere G. Modification of guanine nucleotide-regulatory components in brain membranes. J. Neurosci. 4:1984;2764-2771.
9. Crook S.T. Progress toward oligonucleotide therapeutics: pharmacodynamic properties. FASEB J. 7:1993;533-539.
10. Duttaroy A., Yoburn B.C. The effect of intrinsic efficacy on opioid tolerance. Anesthesiology. 82:1995;1226-1236.
11. Duttaroy A., Kirtman R., Farrell F., Phillips M., Philippe J., Monderson T., Yoburn B.C. The effect of cumulative dosing on the analgesic potency of morphine in mice. Pharmacol. Biochem. Behav. 58:1997;67-71.
12. D.J. Finney, Probit Analysis, 3rd edn., Cambridge University Press, London, 1973.
13. Furchgott R.F. The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. Adv. Drug Res. 3:1966;21-56.
14. i2 transducer proteins. Life Sci. 55:1994;205-212.
15. Hoehn K., Reid A., Sawynok J. Pertussis toxin inhibits antinociception produced by intrathecal injection of morphine, noradrenaline and baclofen. Eur. J. Pharmacol. 146:1988;65-72.
16. Jones D.T., Reed R.R. Molecular cloning of five GTP-binding protein cDNA species from rat olfactory neuroepithelium. J. Biol. Chem. 262:1987;14241-14249.
17. Kalkbrenner F., Dippel E., Wittig B., Schultz G. Specificity of interaction between receptor and G protein: use of antisense techniques to relate G-protein subunits to function. Biochim. Biophys. Acta. 1314:1996;125-139.
18. Lee C.E., Kest B., Jenab S., Inturrisi C.E. Effect of surpraspinal antisense oligodeoxynucleotide treatment on δ-opioid receptor mRNA levels in mice. Mol. Brain Res. 48:1997;17-22.
19. Lutfy K., Chang S.C., Candido J., Jang Y., Sierra V., Yoburn B.C. Modification of morphine-induced analgesia and toxicity by pertussis toxin. Brain Res. 544:1991;191-195.
20. i2. Biochem. J. 267:1990;391-398.
21. Murthy K.S., Makhlouf G.M. Opioid mu, delta, and kappa receptor-induced activation of phospholipase C-beta 3 and inhibition of adenylyl cyclase is mediated by Gi2 and G(o) in smooth muscle. Mol. Pharmacol. 50:1996;870-877.
22. Pasternak G.W. Pharmacological mechanisms of opioid analgesics. Clin. Neuropharmacol. 16:1993;1-18.
23. Probst J.C., Skutella T. Elevated messenger RNA levels after antisense oligodeoxynucleotide treatment in vitro and in vivo. Biochem. Biophys. Res. Commun. 225:1996;861-868.
24. Raffa R.B., Martinez R.P., Connelly C.D. G-protein antisense oligodeoxyribonucleotides and μ-opioid supraspinal antinociception. Eur. J. Pharmacol. 258:1994;R5-R7.
25. i2 alpha antisense oligonucleotide differentiates morphine antinociception, constipation and acute dependence in mice. Life Sci. 58:1996;PL73-76.
26. Rossi G.C., Standifer K.M., Pasternak G.W. Differential blockade of morphine and morphine-6 beta-glucuronide analgesia by antisense oligodeoxynucleotides directed against MOR-1 and G-protein alpha subunits in rats. Neurosci. Lett. 198:1995;99-102.
27. Ruffolo R.R. Review: important concepts of receptor theory. J. Auton. Pharmacol. 2:1982;277-295.
28. Y. Salomon, Adenylate cyclase assay, in: G. Brooker, P. Greengard, G.A Robinson (Eds.), Advances in Cyclic Nucleotide Research 10 (1979) 35-55.
29. Salomon Y., Londos C., Robell M. A highly sensitive adenylate cyclase assay. Anal. Biochem. 58:1974;541-548.
30. S transducer proteins reduced the morphine withdrawal syndrome in mice. Life Sci. 55:1994;PL445-450.
31. sα enhances the supraspinal antinociception induced by morphine, β-endorphin and clonidine in mice. Life Sci. 51:1992;PL237-242.
32. Sánchez-Blázquez P., Garzón J. Pertussis toxin differentially reduces the efficacy of opioids to produce supraspinal analgesia in the mouse. Eur. J. Pharmacol. 152:1988;357-361.
33. Sánchez-Blázquez P., García-España A., Garzón J. In vivo injection of antisense oligodeoxynucleotides to G alpha subunits and supraspinal analgesia evoked by mu and delta opioid agonists. J. Pharmacol. Exp. Ther. 275:1995;1590-1596.
34. Shah S., Breivogel D., Selly D., Munirathinam G., Childers S., Yoburn B.C. Time-dependent effects of in vivo pertussis toxin on morphine analgesia and G-proteins in mice. Pharmacol. Biochem. Behav. 56:1997;465-469.
35. Shah S., Duttaroy A., Chen B.T., Carroll J., Yoburn B.C. The effect of μ-opioid receptor antisense on morphine potency and antagonist-induced supersensitivity and receptor upregulation. Brain Res. Bull. 42:1997;479-484.
36. Shah S., Duttaroy A., Davis T., Yoburn B.C. Spinal and supraspinal effects of pertussis toxin on opioid analgesia. Pharmacol. Biochem. Behav. 49:1994;773-776.
37. Shah S., Duttaroy A., Sehba F., Chen B., Philippe J., Monderson T., Lau-Cam C., Carroll J., Yoburn B.C. The effect of ethanol drinking on opioid analgesia and receptors in mice. Alcohol. 14:1997;361-366.
38. Shen J., Chan K.W., Chen B.T., Philippe J., Sehba F., Duttaroy A., Carroll J., Yoburn B.C. The effect of in vivo ethanol consumption on cyclic AMP and δ-opioid receptors in mouse striatum. Brain Res. 770:1997;65-71.
39. Smith C.A., Aurelian L., Reddy M.P., Miller P.S., Ts'o P.O.P. Antiviral effect of an oligo(nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5. Proc. Natl. Acad. Sci. 83:1986;2787-2791.
40. Standifer K.M., Jenab S., Su W., Chien C., Pan Y., Inturrisi C.E., Pasternak G.W. Antisense oligonucleotides to the cloned delta opioid receptor DOR-1: uptake, stability, and regulation of gene expression. J. Neurochem. 65:1995;1981-1987.
41. Standifer K.M., Rossi G.C., Pasternak G.W. Differential blockade of opioid analgesia by antisense oligodeoxynucleotides directed against various G-protein α subunits. Mol. Pharmacol. 50:1996;293-298.
42. Strathmann M., Simon M.I. G protein diversity: a distinct class of α subunits is present in vertebrates and invertebrates. Proc. Natl. Acad. Sci. USA. 87:1990;9113-9117.
43. Sullivan K.A., Liao Y-C., Alborzi A., Beiderman B., Chang F-H., Masters S.B., Levinson A.D., Bourne H. Inhibitory and stimulatory G proteins of adenylate cyclase: cDNA and amino acid sequences of the α chains. Proc. Natl. Acad. Sci. USA. 83:1986;6687-6691.
44. Tang T., Kiang J.G., Cote T.E., Cox B.M. Antisense oligodeoxynucleotide to the Gi2 protein α subunit sequence inhibits an opioid-induced increase in the intracellular free calcium concentration in ND8-47 neuroblastoma×dorsal root ganglion hybrid cells. J. Pharmacol. Exp. Ther. 48:1995;189-193.
45. van der Krol A.R., Mol J.N.M., Stuitje A.R. Modulation of eukaryotic gene expression by complementary RNA or DNA sequences. Biotechniques. 6:1988;958-976.
46. Wahlestedt C. Antisense oligonucleotide strategies in neuropharmacology. Trends Pharmacol. Sci. 15:1994;42-46.
47. White A.A., Karr D.B. Improved two-step method for the assay of adenylate and guanylate cyclase. Anal. Biochem. 85:1978;451-460.
48. Yoburn B.C., Luke M.C., Pasternak G.W., Inturrisi C.E. Upregulation of opioid receptor subtypes correlates with potency changes of morphine and DADLE. Life Sci. 43:1988;1319-1324.